131
Participants
Start Date
October 31, 2012
Primary Completion Date
April 7, 2023
Study Completion Date
September 12, 2023
brentuximab vedotin
1.8 mg/kg every 3 weeks by IV infusion
bendamustine
70 mg/m\^2 by IV infusion on Days 1 and 2 of 3-week cycle
dacarbazine
375 mg/m\^2 every 3 weeks by IV infusion
nivolumab
3 mg/kg every 3 weeks by IV infusion
Columbia University Medical Center, New York
New York Oncology Hematology, P.C., Albany
James P. Wilmot Cancer Center / University of Rochester Medical Center, Rochester
American Oncology Networks LLC, Bethesda
Virginia Cancer Specialists, PC, Fairfax
Shenandoah Oncology P.C., Winchester
Virginia Commonwealth University Medical Center, Richmond
Oncology and Hematology Assoc of SW VA DBA Blue Ridge Cancer Care, Salem
Prisma Health, Greenville
Georgia Cancer Specialists / Northside Hospital Cancer Institute, Sandy Springs
IACT Health, Columbus
Florida Cancer Affiliates, Trinity
University of Alabama at Birmingham, Birmingham
University of South Alabama - Mitchell Cancer Institute, Mobile
James Cancer Hospital / Ohio State University, Columbus
Oncology Hematology Care, Cincinnati
Karmanos Cancer Institute / Wayne State University, Detroit
Carbone Cancer Center / University of Wisconsin, Madison
Minnesota Oncology Hematology P.A., Minneapolis
Rush University Medical Center, Chicago
Illinois Cancer Specialists / Advocate Lutheran General Hospital, Niles
Nebraska Cancer Specialists, Omaha
Texas Oncology - Presbyterian Cancer Center Dallas, Dallas
Texas Oncology - Longview, Longview
Arlington Cancer Center, Arlington
Texas Oncology - Bedford, Bedford
Texas Oncology - Fort Worth 12th Avenue, Fort Worth
Houston Methodist Cancer Center, Houston
MD Anderson Cancer Center / University of Texas, Houston
Texas Oncology - McAllen, McAllen
Texas Oncology - Seton Williamson, Round Rock
Rocky Mountain Cancer Centers - Aurora, Aurora
Banner MD Anderson Cancer Center, Gilbert
Arizona Oncology Associates, PC - HOPE, Tucson
Comprehensive Cancer Centers of Nevada, Las Vegas
City of Hope National Medical Center, Duarte
Providence St Joseph Medical Center, Burbank
Wilshire Oncology Medical Group Inc., Pomona
Northwest Cancer Specialists, P.C., Tigard
Willamette Valley Cancer Institute and Research Center, Eugene
Benaroya Research Institute/Virginia Mason Medical Center, Seattle
Swedish Cancer Institute, Seattle
Wenatchee Valley Medical Center, Wenatchee
Alaska Urological Institute, Anchorage
Arizona Cancer Center / University of Arizona, Tucson
Highlands Oncology Group, Springdale
Morristown Medical Center/ Carol G. Simon Cancer Center, Morristown
Rutgers Cancer Institute of New Jersey, New Brunswick
Texas Oncology - Denton South, Denton
University of Alberta / Cross Cancer Institute, Edmonton
London Health Sciences Centre - Victoria Hospital, London
CIUSSS de L'Est de l'lle de Montreal / installation Hopital Maisonneuve-Rosemont, Montreal
Jewish General Hospital, Montreal
Royal Victoria Hospital, McGill University Health Centre, Montreal
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Seagen Inc.
INDUSTRY